1. Home
  2. CIK vs GANX Comparison

CIK vs GANX Comparison

Compare CIK & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Credit Suisse Asset Management Income Fund Inc.

CIK

Credit Suisse Asset Management Income Fund Inc.

HOLD

Current Price

$2.81

Market Cap

156.2M

Sector

Finance

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$1.79

Market Cap

159.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CIK
GANX
Founded
1987
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
156.2M
159.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
CIK
GANX
Price
$2.81
$1.79
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$8.00
AVG Volume (30 Days)
115.4K
1.0M
Earning Date
01-01-0001
11-12-2025
Dividend Yield
9.03%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.50
$1.41
52 Week High
$3.19
$4.34

Technical Indicators

Market Signals
Indicator
CIK
GANX
Relative Strength Index (RSI) 42.19 34.89
Support Level $2.79 $1.72
Resistance Level $2.84 $2.07
Average True Range (ATR) 0.02 0.17
MACD -0.00 0.01
Stochastic Oscillator 29.41 10.77

Price Performance

Historical Comparison
CIK
GANX

About CIK Credit Suisse Asset Management Income Fund Inc.

Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. Credit Suisse serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: